Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-1-17
pubmed:abstractText
A major goal of cancer research is to match specific therapies to molecular targets in cancer. Genome-scale expression profiling has identified new subtypes of cancer based on consistent patterns of variation in gene expression, leading to improved prognostic predictions. However, how these new genetic subtypes of cancers should be treated is unknown. Here, we show that a gene module map can guide the prospective identification of targeted therapies for genetic subtypes of cancer. By visualizing genome-scale gene expression in cancer as combinations of activated and deactivated functional modules, gene module maps can reveal specific functional pathways associated with each subtype that might be susceptible to targeted therapies. We show that in human breast cancers, activation of a poor-prognosis "wound signature" is strongly associated with induction of both a mitochondria gene module and a proteasome gene module. We found that 3-bromopyruvic acid, which inhibits glycolysis, selectively killed breast cells expressing the mitochondria and wound signatures. In addition, inhibition of proteasome activity by bortezomib, a drug approved for human use in multiple myeloma, abrogated wound signature expression and selectively killed breast cells expressing the wound signature. Thus, gene module maps may enable rapid translation of complex genomic signatures in human disease to targeted therapeutic strategies.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1538-7445
pubmed:author
pubmed:issnType
Electronic
pubmed:day
15
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
369-78
pubmed:meshHeading
pubmed-meshheading:18199530-Algorithms, pubmed-meshheading:18199530-Antineoplastic Agents, pubmed-meshheading:18199530-Automatic Data Processing, pubmed-meshheading:18199530-Boronic Acids, pubmed-meshheading:18199530-Breast Neoplasms, pubmed-meshheading:18199530-Chromosome Mapping, pubmed-meshheading:18199530-Gene Expression Profiling, pubmed-meshheading:18199530-Gene Expression Regulation, Neoplastic, pubmed-meshheading:18199530-Gene Regulatory Networks, pubmed-meshheading:18199530-Gene Targeting, pubmed-meshheading:18199530-Gene Therapy, pubmed-meshheading:18199530-Genes, Mitochondrial, pubmed-meshheading:18199530-Humans, pubmed-meshheading:18199530-Neoplasm Invasiveness, pubmed-meshheading:18199530-Neoplasms, pubmed-meshheading:18199530-Oligonucleotide Array Sequence Analysis, pubmed-meshheading:18199530-Prognosis, pubmed-meshheading:18199530-Proteasome Endopeptidase Complex, pubmed-meshheading:18199530-Pyrazines, pubmed-meshheading:18199530-Tumor Cells, Cultured, pubmed-meshheading:18199530-Wounds and Injuries
pubmed:year
2008
pubmed:articleTitle
Revealing targeted therapy for human cancer by gene module maps.
pubmed:affiliation
Programs in Epithelial Biology, Stanford University, Stanford, California 94305, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural, Validation Studies